Interpace Biosciences Inc (PK:IDXG)

Mar 07, 2024 08:00 am ET
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fourth quarter and full year ending December 31, 2023. For the fourth quarter, Interpace reported revenue of $10.3 million and...
Nov 08, 2023 03:29 pm ET
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update. Third quarter Net Revenue was $9.1 million, a...
Aug 09, 2023 12:30 pm ET
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financial update. Second quarter Net Revenue was $11.0 million, a...
Jul 10, 2023 03:59 pm ET
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced preliminary business results for the second quarter ending June 30, 2023, and provided an update on recent activities. Final Q2 financial results are expected...
Jun 05, 2023 04:05 pm ET
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS) issued the final Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) which...
May 12, 2023 04:05 pm ET
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2023 and provided a business and financial update. First quarter Net Revenue was $9.8 million....
Mar 27, 2023 04:05 pm ET
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2022 and provided a business and financial update. Fourth quarter Net Revenue...
Nov 14, 2022 04:41 pm ET
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2022 and provided a business and financial update. Third quarter Net Revenue was $8.2 million, a...
Oct 20, 2022 04:28 pm ET
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today...
Sep 01, 2022 05:18 pm ET
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today...
Aug 31, 2022 05:30 pm ET
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.
Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced the closing of a definitive asset purchase agreement under which Flagship Biosciences, Inc. has acquired the...
Aug 15, 2022 04:05 pm ET
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2022 and provided a business and financial update. Second quarter Net Revenue was $9.4 million, a 16%...
May 16, 2022 04:15 pm ET
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6%...
May 11, 2022 08:30 am ET
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience
Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in association with Miroculus, Inc., a developer of revolutionary tools for personal lab automation, it will...
Mar 31, 2022 04:15 pm ET
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2021 and provided a business and financial update. “2021 has been a...
Feb 22, 2022 09:00 am ET
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests
Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the National Correct Coding Initiative (NCCI) program issued a response on behalf of the Centers for Medicare...
Jan 28, 2022 07:35 pm ET
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests
Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling personalized medicine, announced today that it was terminating its previously announced rights offering and the mutual termination of the standby purchase...
Jan 27, 2022 04:05 pm ET
Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director
Interpace Biosciences , Inc. (OTCQX: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2022. Dr....
Jan 12, 2022 04:41 pm ET
Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped Rights Offering of up to $30 million. Under the terms of the Rights Offering, the Company is...
Jan 03, 2022 05:07 pm ET
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it has set the record date for its proposed fully back-stopped $30 Million Rights Offering. Under the terms of the Rights Offering, the Company will...
Nov 10, 2021 04:05 pm ET
Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended September 30, 2021 and provided a business and financial update. “2021 has been a dynamic and meaningful year...
Nov 02, 2021 04:15 pm ET
Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $8 million term loan with BroadOak Fund V, L.P. (“BroadOak”) (the “BroadOak Loan”). The proceeds...
Oct 28, 2021 08:15 am ET
Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today...
Oct 21, 2021 09:15 am ET
Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today...
Oct 15, 2021 09:15 am ET
Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica Bank (the “Bank”). The facility matures on...
Aug 10, 2021 04:05 pm ET
Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended June 30, 2021 and provided a business and financial update. “Following a transformative,...
May 17, 2021 08:00 am ET
Interpace Pharma Solutions Announces New Capability in Spatial Biology/Precision Oncology Services
Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that it will offer a new capability in providing Digital Spatial Profiling services using the novel GeoMx® testing...
May 11, 2021 04:47 pm ET
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update. “We are very pleased with our first...
May 03, 2021 08:00 am ET
Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned subsidiary of Cigna, has updated their laboratory management guidelines to include positive coverage for...
Apr 22, 2021 08:00 am ET
Interpace Biosciences to Explore Strategic Alternatives for Maximizing Shareholder Value
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today issued the following statement. Interpace continues to make progress executing its growth strategy and the Company recently increased 2021 revenue guidance. The...
Apr 19, 2021 07:05 am ET
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally provided on March 31, 2021. "We saw increased and sustained clinical volume activity during the...
Apr 12, 2021 07:05 am ET
Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis
Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies. RNAscope® in situ...
Apr 05, 2021 04:05 pm ET
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis (PLA) code that specifically identifies...
Mar 31, 2021 05:20 pm ET
Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 2020 and provided a business and financial update. “Fiscal 2020 was a challenging and...
Mar 17, 2021 07:30 am ET
Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into a definitive agreement to sell its New Haven CT CLIA certified, CAP accredited laboratory to DiamiR Biosciences, Corp. (DiamiR). This sale is in line with previously...
Mar 09, 2021 09:00 am ET
Interpace Biosciences and XIFIN Forge Strategic Partnership to Improve Financial Performance
Interpace Biosciences, Inc., a leader in molecular testing for cancer risk, today announced that it has expanded its relationship with XIFIN, Inc. to deploy XIFIN’s award-winning revenue cycle management solution, XIFIN RPM 12, enterprise-wide to...
Feb 25, 2021 04:30 pm ET
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
Interpace Biosciences, Inc. (“Interpace” or “the Company”), today announced that Blue Cross Blue Shield of Illinois, owned by Health Care Services Corporation (HCSC) and the largest health plan in Illinois with greater than 8 million covered lives,...
Feb 24, 2021 05:54 pm ET
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today announced that on February 24, 2021, the Company satisfied the requirements for trading of the...
Feb 17, 2021 08:00 am ET
Interpace Biosciences Announces Impending Delisting from Nasdaq
Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on February 16, 2020 it had received notification from the Listing Qualifications Staff (the “Staff”) of The...
Feb 16, 2021 09:21 pm ET
Interpace Biosciences Announces Path Forward in Letter to Shareholders
Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareholders: Dear Shareholders, As the newly appointed President and CEO of Interpace I want to take a...
Feb 04, 2021 04:42 pm ET
Interpace Biosciences Announces CFO Leadership Transition
Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace’s Chief Financial Officer (“CFO”)....
Feb 01, 2021 09:27 am ET
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, used in the...
Jan 28, 2021 09:15 am ET
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida
Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the Company’s Diagnostics group has entered in to a contract with Blue Cross Blue Shield of Florida (“Florida Blue”), the largest health plan in Florida. As part of the Agreement,...
Jan 20, 2021 03:38 pm ET
Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast after the close of market on Thursday, January 21, 2021 at 4:30 p.m. ET.         Purpose: To update...
Jan 20, 2021 08:30 am ET
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) today announced financial results for the fiscal quarter ended September 30, 2020 and provided a business and financial update. Thomas Burnell, President and CEO of...
Nov 25, 2020 08:12 am ET
Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor
Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 2020. He will be replaced as President and Chief Executive Officer by Thomas Burnell, PhD.,...
Nov 19, 2020 04:11 pm ET
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the delay in the...
Oct 26, 2020 06:30 am ET
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays
Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the study entitled “Multiplatform molecular test performance in indeterminate thyroid nodules” was published on-line in the peer-reviewed journal, Diagnostic Cytopathology. This paper...
Oct 20, 2020 08:00 am ET
Interpace Biosciences Announces Second Quarter 2020 Financial and Business Results
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) today announced financial results for the fiscal quarter ended June 30, 2020 and provided a business and financial update. Year to date Net Revenue was $14.6...
Oct 14, 2020 09:31 am ET
Thinking about buying stock in Nio, Heat Biologics, Bed Bath & Beyond, Interpace Biosciences, or Lululemon Athletica?
NEW YORK, Oct. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, HTBX, BBBY, IDXG, and LULU.
Oct 14, 2020 06:30 am ET
Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has completed an independent investigation into complaints of certain employment and billing and compliance...
Aug 20, 2020 08:30 am ET
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on August 18, 2020 received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the delay in the...
Jul 21, 2020 06:05 am ET
Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays
Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that a peer-reviewed manuscript describing results from a seminal clinical validation study of the combination of ThyGeNEXT® and ThyraMIR® has been accepted for publication in the highly...
Jun 25, 2020 04:59 pm ET
Interpace Biosciences Announces First Quarter 2020 Financial and Business Results
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced financial results for the fiscal quarter ended March 31, 2020 and provided a business and financial update. “First quarter revenue was $9.2 million and near the top end of our previously...
Jun 24, 2020 04:20 pm ET
Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020
Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial results on Thursday, June 25, 2020 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Company’s financial results and...
Apr 27, 2020 06:55 am ET
Interpace Biosciences Announces Contract with Lab Benefits Management Firm
Interpace Biosciences (NASDAQ: IDXG) announced today that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions (Avalon), a specialty benefit management company with more than 3 million members, focused...
Apr 22, 2020 04:05 pm ET
Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced financial results for the fiscal year ended December 31, 2019 and provided a business and financial update. “Fiscal 2019 was a transformational year for us as we acquired the Biopharma...
Apr 22, 2020 01:38 pm ET
Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial Results on Wednesday, April 22, 2020
Interpace (IDXG) announced today that it will release its financial results for the fourth quarter and full year 2019 this afternoon. Company management will host a conference call and webcast to discuss its financial results and provide a general...
Mar 11, 2020 09:25 pm ET
Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts
Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts. While terms of this Agreement are not disclosed, Interpace is an...
Mar 10, 2020 06:55 am ET
Interpace Diagnostics Announces Contract with BCBS of Massachusetts
Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts with over 3 million members in Massachusetts and across New England. The...
Mar 02, 2020 06:55 am ET
Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s ThyGeNEXT® and ThyraMIR® tests in the Journal of the American Society of Cytopathology. The article,...
Feb 24, 2020 06:55 am ET
Interpace Announces Extension of LabCorp Agreement
Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that its agreement with LabCorp® (NYSE: LH) has been extended for an additional two years, through January 2022. Interpace and LabCorp initially entered in to their collaboration in 2016...
Feb 11, 2020 06:55 am ET
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics’ ThyraMIR® miRNA classifier for evaluating indeterminate thyroid nodules...
Jan 30, 2020 06:55 am ET
Interpace Biosciences Announces Addition to Board of Directors and Changes in Leadership
Interpace Biosciences , Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Ron Rocca, President & CEO of Exagen, Inc. (NASDAQ: XGN) has been appointed to the Interpace Board of Directors....
Jan 13, 2020 06:55 am ET
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
Interpace Biosciences, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”), a leader in leveraging molecular diagnostics and other platforms for the benefit of patients and supporting pharmaceutical development, today announced that it has entered...
Jan 06, 2020 06:55 am ET
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary, Interpace Diagnostics has entered into a collaborative study aimed at exploring the potential use of...
Dec 17, 2019 06:55 am ET
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Company’s ThyGeNEXT® test, representing an increase of approximately...
Dec 05, 2019 06:55 am ET
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China
Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today announced that it is continuing to expand a previously announced partnership agreement to jointly develop, promote and offer translational studies and clinical trial solutions to...
Dec 02, 2019 06:55 am ET
Interpace Biosciences Launches New Corporate Website
Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and Pharma Solutions businesses of Interpace are represented together on one easy to navigate website. The...
Nov 13, 2019 04:40 pm ET
Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results
Interpace Biosciences, Inc. (formerly Interpace Diagnostics Group, Inc.) (Nasdaq: IDXG), a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to...
Nov 12, 2019 06:55 am ET
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019
Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Company’s financial results and provide...
Nov 04, 2019 06:55 am ET
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility
Interpace Group (NASDAQ: IDXG) Interpace Diagnostics announced today the publication of two peer-reviewed journal articles and one textbook chapter supporting the clinical utility of ThyGeNEXT® when used alone and in combination with ThyraMIR®....
Oct 29, 2019 06:55 am ET
Interpace to Present Data at the ATA Annual Meeting
Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th Annual Meeting of the American Thyroid Association (ATA), being held October 30th to November 3rd, 2019...
Oct 24, 2019 04:15 pm ET
Cancer Genetics, Inc. Announces Strategic Transactions
Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in proprietary preclinical test systems supporting drug discovery and development at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers, today...
Oct 24, 2019 06:55 am ET
Interpace to Present at the American College of Gastroenterology Conference
Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid and GI products at an industry known scientific international meeting. The American College of Gastroenterology annual meeting is held...
Oct 17, 2019 06:55 am ET
Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes the second tranche of the overall $27 million...
Oct 15, 2019 06:55 am ET
Interpace Named to ‘Most Admired Companies’ List
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The Silicon Review. The honorees are chosen by The Silicon Review’s editorial board recognizing companies...
Sep 30, 2019 06:55 am ET
Interpace Announces New Contracts with Multiple Blue Cross Blue Shield Plans
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has contracted with 3 independent Blue Cross Blue Shield (BCBS) plans totaling nearly 5 million covered lives across Alabama, Arkansas, and Arizona. These members of the BCBS...
Sep 18, 2019 06:55 am ET
Interpace to Present at The Ladenburg Thalmann 2019 Healthcare Conference
Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming Ladenburg Thalmann 2019 Healthcare Conference, held on September 24th, 2019 at the Sofitel hotel in New...
Sep 16, 2019 06:55 am ET
Interpace Enters Strategic Partnership Agreement with Genecast Biotechnology to Partner with Biopharma Solutions in China
Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announced that it has entered into a partnership agreement to jointly develop, promote, and offer translational...
Sep 06, 2019 06:55 am ET
Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright
Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming 21st Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., held September 8 - 10, 2019...
Aug 19, 2019 05:15 pm ET
Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through...
Aug 13, 2019 08:15 am ET
Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update
Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced financial results for the second quarter and six months ended June 30, 2019 and reviewed recent business progress. For the second quarter of 2019 Net...
Aug 06, 2019 04:05 pm ET
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results on Tuesday, August 13, 2019
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it will report its second quarter 2019 financial results on Tuesday, August 13, 2019 at 8:30 a.m. ET. Interpace will host a conference call and webcast to discuss the Company’s...
Jul 31, 2019 06:55 am ET
Interpace Diagnostics Announces Contract with Blue Cross Blue Shield of Michigan
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has contracted with Blue Cross Blue Shield (BCBS) of Michigan, a not-for-profit independent member of the Blue Cross Blue Shield Association with 4.5 million members in the...
Jul 29, 2019 06:55 am ET
Interpace Announces Contract with Blue Shield of California for ThyGeNEXT® & ThyraMIR®
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has entered in to a contract with Blue Shield of California, a not-for-profit independent member of the Blue Cross Blue Shield Association making ThyGeNEXT and ThyraMIR tests...
Jul 22, 2019 06:55 am ET
Interpace Announces New Agreement with SelectHealth
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has reached an agreement with SelectHealth (a plan associated with Intermountain Healthcare) to provide its proprietary thyroid cancer assays, ThyGeNEXT® and ThyraMIR® to...
Jul 18, 2019 06:55 am ET
Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial...
Jul 15, 2019 04:10 pm ET
Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), announced today that it has acquired assets and certain liabilities constituting the Biopharma Services business of Cancer Genetics, Inc. (NASDAQ: CGIX) (the...
Jun 20, 2019 06:55 am ET
Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR® tests for thyroid cancer are now covered by Independence Blue Cross (Independence), providing plan benefits coverage for its members who meet...
Jun 13, 2019 06:55 am ET
Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific Officer, will present at the World...
May 13, 2019 04:05 pm ET
Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced financial results for the first quarter ended March 31, 2019, and reviewed recent business progress....
May 09, 2019 06:55 am ET
Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that data from an independent study, which showed that BarreGEN® performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to...
May 06, 2019 06:55 am ET
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019
Interpace Diagnostics Group, Inc., (IDXG:NASDAQ) announced today that it will report its first quarter 2019 financial results after the close of market on Monday, May 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to...
May 01, 2019 06:55 am ET
Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”) announced today that data from its thyroid registry has been published in the peer reviewed publication Diagnostic Cytopathology in a paper called “Clinical impact of...
Apr 25, 2019 06:55 am ET
Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has received the College of American Pathologists (“CAP”) accreditation for its Pittsburgh, Pennsylvania and New Haven, Connecticut laboratories. Only after the Clinical...
Apr 23, 2019 06:55 am ET
Interpace Diagnostics Announces New York State Approval
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has received approval to launch ThyraMIR® diagnostic testing on formalin-fixed, paraffin-embedded (“FFPE”) tissue samples from thyroid nodules from the State of New York....
Apr 12, 2019 09:10 am ET
New Research: Key Drivers of Growth for Capital One Financial, ServiceSource International, Pfenex, eMagin, Interpace Diagnostics Group, and Rubicon Technology — Factors of Influence, Major Initiative
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Capital One Financial Corporation (NYSE:COF), ServiceSource International, Inc....
Apr 02, 2019 06:55 am ET
Interpace Diagnostics Announces New Coverage of Thyroid Testing by Medica
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that Medica, one of the largest health plans spanning numerous states throughout the Midwest, has extended coverage of both ThyGeNEXT™ and ThyraMIR® to its 1.3 million covered lives....
Mar 19, 2019 04:05 pm ET
Interpace Diagnostics Group Reports Full Year and Fourth Quarter 2018 Financial Results
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”) today announced financial results for the full year and fourth quarter ended December 31, 2018, along with business progress and recent accomplishments. Topline...
Mar 04, 2019 06:55 am ET
Interpace Diagnostics Receives Regional Award as 2018 Top Life Sciences Company
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”) announced today that the Pittsburgh Business Times has designated Interpace Diagnostics as its 2018 Top Life Sciences Company award winner. This recognition is granted to those...
Feb 28, 2019 06:55 am ET
Interpace Diagnostics Announces Preliminary 2018 Revenues
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a fully integrated commercial and bioinformatics company, announced preliminary net revenue results for the year ended December 31, 2018:    Annual Net Revenues...
Feb 19, 2019 06:55 am ET
Interpace Diagnostics Announces First Independent Publication Demonstrating Clinical Utility of BarreGEN®
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that BMJ Open Gastroenterology, an on-line, peer-reviewed, open access gastroenterology journal dedicated to publishing high-quality medical research from all disciplines and...
Feb 04, 2019 06:55 am ET
Interpace Diagnostics to Attend BIO CEO & Investor Conference in New York City
Interpace Diagnostics Group (NASDAQ: IDXG) today announced the Company will attend the 21st BIO CEO & Investor Conference being held in New York, NY at the New York Marriott Marquis on February 11th & 12th, 2019. The Company will host one-on-one...
Jan 29, 2019 04:20 pm ET
 Interpace Diagnostics Announces Closing of $7.0 Million Public Offering of Common Stock
Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”) today announced the closing of its previously announced underwritten public offering of 9,333,334 shares of its common stock at a public offering price of $0.75 per...
Jan 25, 2019 06:00 am ET
Interpace Diagnostics Announces Pricing of $7.0 Million Public Offering of Common Stock
Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”) today announced the pricing of an underwritten public offering of 9,333,334 shares of its common stock at a public offering price of $0.75 per share, less underwriting...
Jan 24, 2019 04:35 pm ET
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
Interpace Diagnostics Group, Inc. (Nasdaq: IDXG) (“Interpace” or the “Company”) announced today that it intends to offer and sell shares of its common stock in a registered underwritten public offering. In addition, Interpace also intends to grant...
Jan 24, 2019 06:55 am ET
Interpace Diagnostics to Present at the Fifteenth Annual NobleCon
Interpace Diagnostics Group (NASDAQ: IDXG) today announced that Jack Stover, Chief Executive Officer, will present at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Tuesday,...
Jan 22, 2019 06:55 am ET
Interpace Diagnostics Announces Further Expansion of Thyroid Business
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has finalized the validation of its third specimen type for its molecular thyroid tests ThyGeNEX™ and ThyraMIR®. Interpace has expanded its services again to now also process...
Jan 14, 2019 06:55 am ET
Interpace Diagnostics Enters into Agreement with University of Maryland Medical System
Interpace Diagnostics Group (NASDAQ: IDXG) has entered in to an Agreement with the University of Maryland Medical System (UMMS), which will provide physicians access to ThyGeNEXT™, ThyraMIR®, and PancraGEN® across the entire UMMS network....
Dec 27, 2018 06:55 am ET
Interpace Diagnostics Ranked as Top 10 Bioinformatics Solutions Provider
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that CIO Applications, a publication focused on providing professionals with information on the most comprehensive collection of technology trends, has once again recognized...
Dec 17, 2018 06:50 am ET
Interpace Announces Notice of Allowance from U.S. Patent and Trademark Office Covering BarreGEN®
Interpace Diagnostics Group, Inc. (“Interpace”) (NASDAQ: IDXG) announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for United States Patent Application No. 13/692,727, for methods...
Dec 07, 2018 07:45 am ET
Detailed Research: Economic Perspectives on PayPal, Alphabet, Southern, Interpace Diagnostics Group, Edwards Lifesciences, and Laboratory Corporation of America — What Drives Growth in Today's Competi
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PayPal Holdings, Inc. (NASDAQ:PYPL), Alphabet Inc. (NASDAQ:GOOG), Southern...
Nov 28, 2018 06:55 am ET
Interpace Diagnostics Launches New Websites
Interpace Diagnostics Group (NASDAQ: IDXG) is pleased to announce the launch of its newly designed company website including new product specific sites that allow for increased interactive functionality, enriched content and ease of navigation. In...
Nov 26, 2018 06:55 am ET
Newly Published Data from National Study Supports Interpace Diagnostics’ PancraGEN®
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today a new scientific paper was published and the primary conclusion showed that DNA analysis using PancraGEN® has a favorable impact on patient outcomes particularly in patients with...
Nov 13, 2018 04:17 pm ET
Interpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today...
Nov 09, 2018 06:55 am ET
Interpace Diagnostics to Participate in 9th Annual Craig-Hallum Alpha Select Conference
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that the Company has been invited to participate at the 9th Annual Craig-Hallum Alpha Select Conference to be held on November 15, 2018 at the Sheraton New York Times Square Hotel....
Nov 07, 2018 08:06 am ET
Interpace Diagnostics Announces New Coverage by Blue Cross Blue Shield for Thyroid Testing
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that the Blue Cross Blue Shield (“BCBS”) Federal Employee Health Benefit Program (“FEHBP”) has extended coverage of ThyGeNEXT™ and ThyraMIR® to its 5.3 million covered lives including...
Nov 07, 2018 06:55 am ET
Interpace Diagnostics Announces New Coverage by Blue Cross Blue Shield for Thyroid Testing
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that the Blue Cross Blue Shield (“BCBS”) Federal Employee Health Benefit Program (“FEHBP”) has extended coverage of ThyGeNEXT™ and ThyraMIR® to its 5.3 million covered lives...
Nov 06, 2018 06:55 am ET
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Tuesday, November 13, 2018
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it will report its third quarter 2018 financial results after the close of market on Tuesday, November 13, 2018 at 4:30 p.m. ET. Following the announcement, Interpace will host a...
Oct 30, 2018 08:45 am ET
Report: Exploring Fundamental Drivers Behind Century Aluminum, Insteel Industries, Altisource Portfolio Solutions S.A, Enova International, Stewart Information Services, and Interpace Diagnostics Grou
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Century Aluminum Company (NASDAQ:CENX), Insteel Industries, Inc....
Oct 24, 2018 06:55 am ET
Interpace Diagnostics Announces Participation at the DJCON18
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), announced today that the Company will present at the upcoming Dawson James 4th Annual Small Cap Growth Conference (“DJCON18”) being held on October 29th 30th, 2018...
Oct 22, 2018 06:55 am ET
Interpace Diagnostics to Present at the 36th Annual Lab Institute 2018
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that the Company has been selected to present at the 36th annual Lab Institute 2018, being held in Washington, DC on Capitol Hill from October 24-26, 2018. As part of the “Adding...
Oct 15, 2018 06:55 am ET
Interpace Diagnostics Presents Favorable New Data at the 88th Annual Meeting of the American Thyroid Association (ATA)
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced that the Company presented new data at the 88th Annual Meeting of the American Thyroid Association (ATA) on Friday, October 5th supporting its molecular tests for thyroid cancer. The new...
Oct 10, 2018 08:30 am ET
Interpace Diagnostics CEO Provides Corporate Update
Interpace Diagnostics Group (NASDAQ: IDXG) is pleased to provide a corporate update to shareholders on current business activities from its Chief Executive Officer, Jack Stover. “I would like to share my gratitude for each of you and my confidence...
Oct 04, 2018 06:55 am ET
Interpace Diagnostics Enters into Agreement with Renowned Integrated Health System
Interpace Diagnostics Group (NASDAQ: IDXG) reported today that it has entered in to an Agreement with Piedmont Healthcare, Georgia’s largest healthcare system with nearly 600 locations, including 11 hospitals, that serves 2 million patients...
Oct 01, 2018 06:55 am ET
Interpace Diagnostics to Present New Data at the 88th Annual Meeting of the American Thyroid Association (ATA) on October 5th
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it will be presenting new data from a multi-center Clinical Experience Study at the 88th Annual Meeting of the American Thyroid Association being held on October 5th in...
Sep 25, 2018 07:55 am ET
Report: Exploring Fundamental Drivers Behind Ocean Power Technologies, Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, Fanhua, and Parsley Energy — New Horizons, Emerging Trends, an
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ocean Power Technologies, Inc. (NASDAQ:OPTT), Amicus Therapeutics, Inc....
Sep 24, 2018 06:55 am ET
Interpace Diagnostics Announces Reimbursement Expansion of ThyGeNEXT™
Interpace Diagnostics Group, Inc. (IDXG), announced today that it has received approval to launch its newest thyroid product, ThyGeNEXT™, in the States of Pennsylvania and New York. The Pennsylvania approval is final and the New York State...
Sep 17, 2018 08:30 am ET
Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides beneficial molecular diagnostic tests and pathology services that improve patient diagnosis and...
Aug 27, 2018 08:30 am ET
INTERPACE DIAGNOSTICS ANNOUNCES PARTICIPATION AT THE 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE SPONSORED BY H.C.WAINWRIGHT & CO.
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient...
Aug 20, 2018 04:30 pm ET
Interpace Diagnostics to Present at the 10th Annual Next Generation Dx Summit 2018
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient...
Aug 15, 2018 08:30 am ET
Interpace Diagnostics Acquires Select Assets of Rosetta Genomics Out of Bankruptcy
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated bioinformatics and commercial company that provides clinically useful molecular diagnostic tests, related first line assessments and pathology...
Aug 09, 2018 04:46 pm ET
Interpace Diagnostics Group Reports Second Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated bioinformatics and commercial company that provides clinically useful molecular diagnostic tests, related first line assessments and pathology...
Aug 01, 2018 08:30 am ET
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Thursday, August 9, 2018
Interpace Diagnostics Group, Inc., (“Interpace” or “the Company”) announced today that it will report its second quarter 2018 financial results after the close of market on Thursday, August 9, 2018 at 4:30 p.m. ET. Following the announcement,...
Jul 31, 2018 08:30 am ET
Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient...
Jul 31, 2018 07:40 am ET
Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), Interpace Diagnostics Group, Inc....
Jul 30, 2018 08:20 am ET
Report: Exploring Fundamental Drivers Behind Chemed, Sysco, Interpace Diagnostics Group, Navient, CenturyLink, and DENTSPLY SIRONA — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Chemed Corporation (NYSE:CHE), Sysco Corporation (NYSE:SYY), Interpace...
Jul 26, 2018 08:37 am ET
Interpace Diagnostics Announces CIGNA’s Expansion of Coverage to Now Include ThyraMIR®
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and...
Jul 19, 2018 08:30 am ET
Interpace Diagnostics Expands Application of Pancreatic Cancer Test
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (the “Company” or “Interpace Diagnostics”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved...
Jun 11, 2018 08:00 am ET
Interpace Diagnostics Announces Coverage of Thyroid Testing by Blue Cross Blue Shield of Florida
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully-integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient...
Jun 04, 2018 08:30 am ET
Interpace Diagnostics to Attend and Present at the 8th Annual LD Micro Invitational Conference
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient...
Jun 01, 2018 08:30 am ET
Interpace Diagnostics Presents New Data on PancraGEN® at Digestive Disease Week
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (the “Company” or “Interpace”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient...
May 30, 2018 08:30 am ET
Interpace Diagnostics Enters into Agreement with Nationally Renowned Institution
Interpace Diagnostics Group (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and...
May 15, 2018 08:00 am ET
Interpace Diagnostics Group Reports First Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated bioinformatics and commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient...
May 14, 2018 08:30 am ET
Interpace Diagnostics Announces Launch of New Thyroid Test
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests, bioinformatics, and pathology services for improved...
May 11, 2018 09:10 am ET
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results, Business Progress and Recent Accomplishments on Tuesday, May 15, 2018
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient...
May 10, 2018 09:00 am ET
Interpace Diagnostics Announces Expanded Coverage Among Blue Cross Blue Shield Plans
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests, bioinformatics, and pathology services for improved...
Apr 18, 2018 08:30 am ET
Interpace Diagnostics Enters Agreement with One of the Largest, Integrated Health Systems in the US
Agreement with BJC Healthcare Covers Both of the Company’s Thyroid Tests
Apr 16, 2018 08:25 am ET
Detailed Research: Economic Perspectives on AmerisourceBergen, Builders FirstSource, Twilio, Gannett Co., Intel, and Interpace Diagnostics Group — What Drives Growth in Today's Competitive Landscape
NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AmerisourceBergen Corporation (NYSE:ABC), Builders FirstSource, Inc....
Apr 02, 2018 08:30 am ET
Interpace Diagnostics Announces Coverage of Its Thyroid Assays by Blue Shield of California
Major California-Based Health Plan Adds Coverage for Both ThyGenX® & ThyraMIR®
Mar 28, 2018 08:30 am ET
Interpace Diagnostics Announces Agreement with Acupath Laboratories
Agreement Provides Additional Resources to Commercialize Thyroid Tests
Mar 20, 2018 08:00 am ET
Interpace Diagnostics Announces Expansion of LabCorp National Agreement
LabCorp’s Dianon Pathology Specialty Laboratory to Provide Cytopathology Services
Mar 15, 2018 04:01 pm ET
Interpace Diagnostics Group Reports Fourth Quarter and Full Year 2017 Financial Results, Business Progress Against Plan and Recent Accomplishments
Revenue for the Quarter Grew 40% over the Comparable Prior Year Quarter and 21% for the Full Year, Raising $30 Million in Equity and Significantly Improving Balance Sheet and Cash Position, Reimbursement Continued to Grow Especially for ThyGenX® and ThyraMIR®                                                Conference Call...
Mar 14, 2018 02:30 pm ET
Interpace Diagnostics Announces Timing of Earnings Release and Investor Conference Call
PARSIPPANY, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (the “Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services, announced today that it will release...
Mar 09, 2018 07:45 am ET
New Research Coverage Highlights Great Western, Acadia Realty Trust, Interpace Diagnostics Group, Abercrombie & Fitch, United Rentals, and ZIOPHARM Oncology — Consolidated Revenues, Company Growth, an
NEW YORK, March 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Great Western Bancorp, Inc. (NYSE:GWB), Acadia...
Mar 08, 2018 08:00 am ET
Interpace Diagnostics Announces Additional Coverage of Thyroid Tests
Four More Blue Cross Blue Shield Plans to Cover ThyGenX® and ThyraMIR® Representing Over 5 million New Members with Coverage
Feb 26, 2018 08:30 am ET
Horizon Blue Cross Blue Shield of New Jersey to Cover Interpace’s Molecular Thyroid Tests
New Jersey’s Largest Health Plan Adds Coverage for Another 3.8 Million Lives
Feb 22, 2018 01:00 pm ET
Interpace Diagnostics’ CEO Interviewed on The RedChip Money Report
PARSIPPANY, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis...
Feb 12, 2018 09:00 am ET
Interpace Diagnostics to Present Data on Thyroid, Pancreatic, and Lung Assays
Company Products Highlighted at USCAP International Meeting
Jan 25, 2018 08:00 am ET
Interpace Diagnostics to Present at NobleCon14 on January 29
PARSIPPANY, N.J. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- INTERPACE DIAGNOSTICS GROUP, INC.(NASDAQ:IDXG), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced...
Jan 08, 2018 08:00 am ET
Interpace Diagnostics Recognized as One of the Top 20 Bioinformatics Solutions Providers
Company Focusing on Leveraging Data from Over 45,000 Patients
Dec 18, 2017 08:00 am ET
Interpace Diagnostics Announces Agreement with ARUP Laboratories
New Agreement Provides Access to Interpace’s Molecular Products
Nov 29, 2017 07:50 am ET
Market Trends Toward New Normal in Cloudera, C.R. Bard, Jabil Circuit, Valero Energy, Navient, and Interpace Diagnostics Group — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Nov. 29, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cloudera, Inc. (NYSE:CLDR), C.R. Bard, Inc....
Nov 16, 2017 08:00 am ET
Interpace Diagnostics Announces New York State Approval of New Product
New York State Issues License for Marker of Aggressiveness in Thyroid Cancer
Nov 13, 2017 08:00 am ET
Interpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent Accomplishments
Q3-2017 Net Revenues of Over $4 Million Growing 27% Over Prior Year Quarter  Represents Fourth Straight Quarter of Sequential Revenue GrowthNet Loss for the Quarter & Year to Date a 56% and 51% Improvement Over Prior Year CMS Approved 40%...
Nov 09, 2017 07:30 am ET
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Business Progress on Monday November 13, 2017
PARSIPPANY, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management,...
Sep 21, 2017 08:30 am ET
Interpace Diagnostics’ CEO Interviewed on The RedChip Money Report
PARSIPPANY, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced that Jack Stover, Interpace’s President and CEO, was interviewed on The RedChip Money Report television program. The interview will air Sunday, September 24, at 12:30 p.m. ET on American Business TV on The Family Channel, available in 100 million homes across the U.S....
Sep 11, 2017 08:00 am ET
Interpace Diagnostics Announces New CPT Code for Reimbursement of Molecular Thyroid Test
PARSIPPANY, N.J., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that the American Medical Association (AMA) has assigned a new, discreet CPT (Current Procedural Technology) code to facilitate reimbursement of ThyraMIR, the Company’s proprietary miRNA-based molecular test for indeterminate thyroid nodules.   The new code, 0018U, is associated wi...
Aug 31, 2017 08:00 am ET
Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Closing Bid Price
PARSIPPANY, N.J., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (the “Company” or “Interpace”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced that on August 30, 2017, the Company received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with Listing Rule 5550(a)(2), which requires maintenance of a minimum closing bid price of the Company’s common stock of $1.00 per share or greate...
Aug 09, 2017 04:05 pm ET
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Thursday August 10, 2017
PARSIPPANY, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that it will report its second quarter 2017 financial results at the close of market on Thursday August 10, 2017. Following the announcement, Interpace's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and ...
Aug 01, 2017 08:00 am ET
Interpace Diagnostics Launches Product Extension at World Conference on Thyroid Cancer
BOSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or the “Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, announced the formal launch of the TERT marker of aggressiveness in indeterminate thyroid nodules at the Third World Congress on Thyroid Cancer being held in Boston, MA through Saturday, July 29th.   Over 1200 domestic and international delegates gathered during the meeting.  Along with launching TERT, the Company served as a major sponsor of the event ...
Jul 27, 2017 08:00 am ET
Interpace Diagnostics Announces Cigna Coverage of ThyGenX®
PARSIPPANY, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that Cigna, one of the largest national health plans in the United States, has agreed to cover Interpace’s ThyGenX® test for Cigna’s 15 million members nationwide, with coverage effective immediately.  Cigna’s coverage combined with Aetna, United Healthcare, Medicare, and other paye...
Jul 13, 2017 02:19 pm ET
Interpace Diagnostics Joins the Fight Against Pancreatic Cancer at the Pittsburgh PurpleStride Event
PARSIPPANY, N.J., July 13, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics (Nasdaq:IDXG) has joined the Pancreatic Cancer Action Network (PanCAN) to raise critical funds and awareness for pancreatic cancer through the Pittsburgh PurpleStride Event. Employees and their families have united to create Team Interpace with a goal of raising $5,000 to support PanCAN’s mission to advance research, support patients and create hope....
May 24, 2017 05:10 pm ET
Interpace Diagnostics Announces Launch of Enhancement to Thyroid Testing Services
PARSIPPANY, N.J., May 24, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company" or "Interpace Diagnostics"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis, announced today that the Company is launching a new biomarker to be ordered along with its current molecular thyroid testing options. The TERT marker is a strong molecular predictor of the aggressiveness of thyroid cancer and adds additional insights in to a patients' molecular profile.  Currently, the Th
May 15, 2017 09:30 am ET
Interpace Diagnostics Group Reports First Quarter 2017 Financial Results, Business Progress and Recent Accomplishments
PARSIPPANY, N.J., May 15, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (IDXG) ("Interpace" or "the Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced financial results and business progress for the quarter ended March 31, 2017, as well as recent accomplishments.
May 12, 2017 03:27 pm ET
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results on Monday May 15, 2017
PARSIPPANY, N.J., May 12, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, announced today that it will report its first quarter 2017 financial results after the close of market on Monday May 15, 2017. Following the announcement, Interpace's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and business progress.
May 10, 2017 09:10 am ET
Interpace Diagnostics Presents New Data on PancraGEN® at DDW
CHICAGO, May 10, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company" or "Interpace Diagnostics"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today the data presented in six posters at this week's Digestive Disease Week (DDW) meeting held May 6th-9th at the McCormick Center in Chicago, Illinois.
May 01, 2017 09:30 am ET
Interpace Diagnostics to Present New Data in Six Posters Related to PancraGEN™ at Upcoming Annual DDW International Meeting on May 6-9, 2017
PARSIPPANY, N.J., May 1, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company" or "Interpace Diagnostics"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today the acceptance of 6 abstracts that will be presented as posters at the upcoming Digestive Disease Week (DDW) meeting being held May 6th-9th, 2017 in Chicago, Illinois. Three abstracts address the utility of PancraGEN™ in assessing long-term risk of malignancy in pancreatic cy
Apr 24, 2017 09:00 am ET
Interpace Diagnostics to Present at RedChip's Global Online Growth Conference
PARSIPPANY, N.J., April 24, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company"), A fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, is scheduled to present at RedChip's Global Online Growth Conference on Wednesday, April 26, 2017, at 1:30 p.m. Eastern time. The presentation can be viewed at www.RedChip.com. A live Q&A session will follow the investor presentation.   
Apr 20, 2017 09:08 am ET
Interpace Diagnostics Eliminates Long Term Secured Debt
PARSIPPANY, N.J., April 20, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company" or "Interpace Diagnostics"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced that it has converted all of the Company's remaining long-term secured outstanding debt into Common Stock and no longer has any secured debt outstanding.  
Apr 18, 2017 09:00 am ET
Interpace Announces Coverage of ThyraMIR® with UnitedHealthcare
PARSIPPANY, N.J., April 18, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that UnitedHealthcare, the largest health plan in the United States, has agreed to cover Interpace's ThyraMIR® test used in assessing indeterminate thyroid nodule fine needle aspirate (FNA) biopsies. The coverage is now in effect and is subject to members' specific benefit plan design. The UnitedHealthcare policy decision is consistent with
Apr 13, 2017 09:45 am ET
Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement
PARSIPPANY, N.J., April 13, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that on April 10, 2017 the Company received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with Listing Rule 5550(b)(1), which requires maintenance of a minimum of $2.5 million stockholders' equity in order to remain listed on The Nasdaq Capital Market.
Apr 03, 2017 09:10 am ET
Interpace Diagnostics Announces European Patent Approval For Underlying Technology of its ThyraMIR® microRNA Classifier
PARSIPPANY, N.J., April 3, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) ("Interpace" or "the Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced that on March 29th 2017, the European Patent Office granted it a Patent for use of microRNAs for distinguishing benign from malignant thyroid neoplasms.  This patent covers the underlying technology of the Company's ThyraMIR® microRNA Classifier.
Mar 29, 2017 05:01 pm ET
Interpace Diagnostics Group Reports Fourth Quarter and Full Year 2016 Financial Results, Business Progress Against Plan and Recent Accomplishments
PARSIPPANY, N.J., March 29, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) ("Interpace" or "the Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced financial results and business progress for the quarter and full year ended December 31, 2016 as well as recent accomplishments.
Mar 28, 2017 05:05 pm ET
Interpace Diagnostics Group Announces Timing of Earnings Release and Investor Conference Call
PARSIPPANY, N.J., March 28, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, announced today that it will release 2016 year end and fourth quarter financial results on Wednesday, March 29, 2017 after the stock market closes. The Company will also host an investor conference call on Wednesday at 4:30 pm EDT.
Mar 23, 2017 10:00 am ET
Interpace Diagnostics Group Announces Agreements to Successfully Restructure Debt and Terminate Royalty and Milestone Obligations
PARSIPPANY, N.J., March 23, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that it has entered into agreements to successfully restructure its secured debt with the former RedPath Shareholders ("RedPath") and concurrently terminate its royalty and milestone obligations.
Mar 20, 2017 09:00 am ET
Interpace Diagnostics Participates in USA Today Endocrine Health Campaign
PARSIPPANY, N.J., March 20, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced its participation in a major awareness campaign on Endocrine Health published in a special insert in the March 17-19th edition of USA Today in several key markets including New York, Los Angeles, Dallas, South Florida, and New Orleans. The information from the campaign is also available on the following digital site: http://www.futureofpersonalhealth.com/
Feb 27, 2017 08:00 am ET
Interpace Diagnostics to Present New Data on Thyroid Product Performance
PARSIPPANY, N.J., Feb. 27, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, announced today the acceptance of four posters to be presented at the upcoming United States and Canadian Academy of Pathology (USCAP) meeting being held March 4-10, 2017 in San Antonio, Texas.
Feb 21, 2017 08:00 am ET
Interpace Diagnostics Enters into Collaborative Agreement with Viatar CTC Solutions to Detect and Characterize Early Cancer in Liquid Biopsies
PARSIPPANY, N.J., Feb. 21, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" or the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced the initiation of a collaborative research program with Viatar CTC Solutions Inc. (Viatar), the cancer dialysis company.
Feb 10, 2017 02:30 pm ET
Interpace Diagnostics to Present at 2017 BIO CEO & Investor Conference
PARSIPPANY, N.J., Feb. 10, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (IDXG) ("Interpace" or the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that its President & Chief Executive Officer, Jack E. Stover, will deliver a corporate presentation at the 2017 BIO CEO & Investor Conference, being held February 13-14, 2017 at the Waldorf Astoria Hotel in New York. 
Feb 08, 2017 11:32 am ET
Interpace Diagnostics Announces Closing of $3.9 Million Public Offering
PARSIPPANY, N.J., Feb. 8, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (IDXG)("Interpace" or the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced the closing of its previously announced underwritten public offering of 1,200,000 shares of common stock at a public offering price of $3.00 per share, as well as 108,000 additional shares of common stock pursuant to the exercise in full of the over-allotment option granted to the underwriters.
Feb 03, 2017 09:00 am ET
Interpace Diagnostics Announces Pricing of Public Offering to Raise $3.6 Million
PARSIPPANY, N.J., Feb. 3, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (IDXG)("Interpace" or the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced the pricing of an underwritten public offering of 1,200,000 shares of common stock with a public offering price of $3.00.  The Company expects to receive gross proceeds of approximately $3.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses.  The Company has granted the representative of
Feb 02, 2017 04:14 pm ET
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
PARSIPPANY, N.J., Feb. 2, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" or the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. The Company intends to use the net proceeds of the offering for working capital, repayment of indebtedness and other liabilities, and general corporate purposes.
Jan 25, 2017 09:07 am ET
Interpace Diagnostics to Present at NobleCon13
PARSIPPANY, N.J., Jan. 25, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc., (NASDAQ: IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risks of cancer, announced today that Jack E. Stover, President & CEO, will present at the NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida, on Tuesday, January 31, 2017, at 12:00 p.m. Eastern Standard Time, in Room 3.
Jan 24, 2017 08:00 am ET
Interpace Diagnostics Announces International Expansion of Thyroid Testing
PARSIPPANY, N.J., Jan. 24, 2017 /PRNewswire/ -- Interpace Diagnostics Corp. (NASDAQ: IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services, announced today its most recent entrée into expanding its commercial foot print internationally as a result of the adoption of the ThyGenX test by Dr. Richard Payne of Montreal, Quebec. This is the Company's initial step in launching its Thyroid products in Canada and, if successful, plans are already in place to expand in to other Provinces and work with the Canadian Health Ministry to secure coverage of both
Jan 20, 2017 12:30 pm ET
Interpace Diagnostics Announces $4.0 Million Registered Direct Offering of Common Stock
PARSIPPANY, N.J., Jan. 20, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" or the "Company"), a company that provides clinically useful molecular diagnostic tests and pathology services, today announced that it has entered into a securities purchase agreement with three  institutional investors to purchase an aggregate of 855,000 shares of common stock in a registered direct offering.  In a concurrent private placement, the Company has agreed to sell to the same investors warrants to purchase 855,000 shares of its common stock with an exercise price of $4.69
Jan 20, 2017 08:00 am ET
Interpace Diagnostics Announces New Partnership with Israeli Specialty Services Provider
PARSIPPANY, N.J., Jan. 20, 2017 /PRNewswire/ -- Interpace Diagnostics Corp. ("Interpace" or the "Company") (NASDAQ: IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risks of cancer, announced today that the Company has entered in to an Agreement (the "Agreement") with Best Med Opinion Ltd ("Best Med") of Tel Aviv, Israel, a provider of second opinion and clinical services for physicians and patients in Israel and several other countries. 
Jan 17, 2017 08:00 am ET
Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
PARSIPPANY, N.J., Jan. 17, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc., (NASDAQ: IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risks of cancer, announced today that it has received a letter dated January 13, 2017 from the NASDAQ Listing Qualifications notifying the Company that it has regained compliance with the requirement of the NASDAQ Stock Market to maintain a minimum closing bid price of $1.00 per share.
Jan 03, 2017 03:58 pm ET
Interpace Diagnostics Announces $4.2 Million Registered Direct Offering of Common Stock
PARSIPPANY, N.J., Jan. 3, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" or the "Company"), a company that provides clinically useful molecular diagnostic tests and pathology services, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase an aggregate of 375,000 shares of common stock at a price of $6.75 per share and an aggregate of 255,000 pre-funded warrants to purchase common stock, at a purchase price of $6.74 per share, with $0.01 per share payable upon exercise of each pre-funded war

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.